Europe begins review of AstraZeneca COVID drug application

The European Medicines Regulator said it has begun reviewing AstraZeneca’s application for an antibody-based therapy for COVID-19, a key step towards approval of the treatment in the region, but did not provide a timeline for review.

Share this post:

Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner